Treatment of Endometriosis with the GnRHa Deslorelin and Add-Back Estradiol and Supplementary Testosterone

What Was Tested

Researchers studied Triptorelin and Deslorelin in the context of endometriosis in this randomized controlled trial publication.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, women only.

Women with pelvic pain and laparoscopically confirmed endometriosis were treated with a six-month course of daily intranasal D with concurrent administration of either transdermal E2, intranasal E2, or intranasal E2 + T.

Safety parameters included assessment of endometrial hyperplasia, bone mineral density (BMD), and hot flashes.

How the Study Was Run

The design is described as randomized, open-label, multicenter and pilot.

Because people in this Triptorelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label Triptorelin study: the participants and staff both knew the treatment.

Running at several centres spread the Triptorelin study over different clinics and patient groups.

It is described as a pilot, a small early test of whether a larger Triptorelin study would be practical.

Cognition and quality of life were also assessed.

What Was Measured

The subject headings attached to it are Endometriosis, Enzyme Inhibitors, Estradiol, Testosterone and Triptorelin Pamoate.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Triptorelin and Deslorelin in people with endometriosis.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (BioMed research international), a journal based in United States.

More context: the Triptorelin compound page and the Deslorelin compound page, Endometriosis research.